Document is current
Any future updates will be listed below
-
Authors
Schiffman, Joshua S. https://orcid.org/0000-0002-1028-1438
D’Avino, Andrew R.
Prieto, Tamara https://orcid.org/0000-0002-1181-9156
Pang, Yakun
Fan, Yilin
Rajagopalan, Srinivas
Potenski, Catherine
Hara, Toshiro https://orcid.org/0000-0002-4389-3393
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
Gawad, Charles https://orcid.org/0000-0002-4728-8203
Landau, Dan A. https://orcid.org/0000-0003-2346-9541
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 21 August 2024
First Online: 24 September 2024
Competing interests
: M.L.S. is equity holder, scientific co-founder and advisory board member of Immunitas Therapeutics. C.G. is a co-founder, equity holder and board member of BioSkryb Genomics. D.A.L. has served as a consultant for Abbvie, AstraZeneca and Illumina and is on the Scientific Advisory Board of Mission Bio, Pangea, Alethiomics, Montage Bio and Veracyte; D.A.L. has received prior research funding from BMS, 10x Genomics, Ultima Genomics and Illumina unrelated to the current manuscript. A.R.D. is a consultant for Montage Bio. The other authors declare no competing interests.
